ライフサイエンスコーパス: macroglobulinemia

1 (CLL), mantle cell lymphoma, and Waldenstrom macroglobulinemia.

2 geting, such as interleukin-6 in Waldenstrom macroglobulinemia.

3 ts with mantle cell lymphoma and Waldenstrom macroglobulinemia.

4 ly analyzed from patients with Waldenstrom's macroglobulinemia.

5 in significance, and 1 case of Waldenstrom's macroglobulinemia.

6 ations are highly prevalent in Waldenstrom's macroglobulinemia.

7 oldering plasma cell myeloma, or Waldenstrom macroglobulinemia.

8 yloidosis, multiple myeloma, and Waldenstrom macroglobulinemia.

9 fe in pretreated patients with Waldenstrom's macroglobulinemia.

10 hich is mutated in a fraction of Waldenstrom macroglobulinemia.

11 marginal zone B-cell lymphoma or Waldenstrom macroglobulinemia.

12 observed in the pathogenesis of Waldenstrom macroglobulinemia.

13 at regulate tumor progression in Waldenstrom macroglobulinemia.

14 cytic lymphoma with or without Waldenstrom's macroglobulinemia (10).

15 th heavily pretreated MM (22) or Waldenstrom macroglobulinemia (3) were administered selinexor (3-60

16 all, and a 3-fold higher risk of Waldenstrom macroglobulinemia, a low-grade lymphoma.

17 Among the patients with Waldenstrom's macroglobulinemia, a somatic variant (T-->C) in LPL cell

18 es from 49 of 54 patients with Waldenstrom's macroglobulinemia and in 3 of 3 patients with non-IgM-se

19 2), previously associated with Waldenstrom's macroglobulinemia and lymphoplasmacytoid lymphoma.

20 n be useful in differentiating Waldenstrom's macroglobulinemia and non-IgM LPL from B-cell disorders

21 The records of patients with Waldenstrom macroglobulinemia and OCT documentation of serous macula

22 Two patients with Waldenstrom's macroglobulinemia and one patient with HD achieved a PR.

23 Four patients (8 eyes) with Waldenstrom macroglobulinemia and serous retinal detachment were ide

24 marginal zone lymphoma, 29 with Waldenstrom macroglobulinemia, and 57 with B-cell chronic lymphoprol

25 ign monoclonal IgM gammopathy, Waldenstrom's macroglobulinemia, and diffuse large B cell lymphoma.

26 Multiple myeloma and Waldenstrom macroglobulinemia are incurable hematologic malignancies

27 ll lines, as well as a CD56(-) Waldenstrom's macroglobulinemia cell line.

28 NF-kappaB nuclear staining, in Waldenstrom's macroglobulinemia cells expressing MYD88 L265P.

29 diffuse large B-cell lymphoma, Waldenstroms macroglobulinemia, chronic lymphocytic leukemia and mult

30 myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plas

31 values for non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thyroiditis wer

32 sal in multiple myeloma, whereas Waldenstrom macroglobulinemia generally does not harbor translocatio

33 malities in multiple myeloma and Waldenstrom macroglobulinemia have implications for disease progress

34 entified in 50% of patients with Waldenstrom macroglobulinemia, however.

35 clonal IgM from a patient with Waldenstrom's macroglobulinemia hydrolyzed Abeta40 at the Lys-28-Gly-2

36 ents (relative risk [RR], 14.8), Waldenstrom macroglobulinemia in 6 (RR, 262), primary amyloidosis in

37 Waldenstrom macroglobulinemia is a distinct low-grade lymphoprolifer

38 Waldenstrom macroglobulinemia is a similar disease with secretion of

39 Waldenstrom's macroglobulinemia is an incurable, IgM-secreting lymphop

40 the International Workshop on Waldenstrom's Macroglobulinemia (IWWM).

41 ma, a myopathy associated with Waldenstrom's macroglobulinemia, Lambert-Eaton myasthenic syndrome, an

42 4.3), lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM; RR = 4.0; 1.5-11), and chroni

43 large B-cell lymphoma and 90% of Waldenstrom macroglobulinemia, making it conceptually attractive to

44 eloid leukemia/myelofibrosis and Waldenstrom macroglobulinemia/myeloma.

45 non-Hodgkin lymphoma (n = 1359), Waldenstrom macroglobulinemia (n = 165), and cryoglobulinemia (n = 5

46 multiple myeloma (n = 2, 11%), Waldenstrom's macroglobulinemia (n = 2, 11%), extranodal marginal zone

47 (Richter transformation; n = 7), Waldenstrom macroglobulinemia (n = 4), and marginal zone lymphoma (n

48 sue samples from patients with Waldenstrom's macroglobulinemia or non-IgM LPL and in B cells from hea

49 Observations: Waldenstrom macroglobulinemia remains a rare, incurable cancer, with

50 Following profiling, Waldenstrom macroglobulinemia samples clustered with chronic lymphoc

51 ng performed after separation of Waldenstrom macroglobulinemia samples into populations with plasma c

52 hology revealed that plasma cell Waldenstrom macroglobulinemia samples most closely resembled multipl

53 ival of patients with smoldering Waldenstrom macroglobulinemia (SWM).

54 ring mutation in patients with Waldenstrom's macroglobulinemia that can be useful in differentiating

55 emic treatment of the underlying Waldenstrom macroglobulinemia, the visual prognosis was guarded.

56 -old white man with history of Waldenstrom's macroglobulinemia transforming to large B-cell lymphoma

57 ow biopsy specimen, diagnosis of Waldenstrom macroglobulinemia was established, and computed tomograp

58 rabine in Patients With Advanced Waldenstrom Macroglobulinemia) was undertaken in 101 centers in five

59 which progresses to lymphoma or Waldenstrom macroglobulinemia, whereas IgA and IgG MGUS progress to

60 s from HID or individuals with Waldenstrom's macroglobulinemia who do not have joint disease.

61 n 63 symptomatic patients with Waldenstrom's macroglobulinemia who had received at least one previous

62 addition, 2 of 3 patients with Waldenstrom's macroglobulinemia who had wild-type MYD88 had somatic va

63 LPL cells in 30 patients with Waldenstrom's macroglobulinemia, with paired normal-tissue and tumor-t

64 ents with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal disease to add

65 oliferative disorders, including Waldenstrom macroglobulinemia (WM) and chronic lymphocytic leukemia,

66 atment options for patients with Waldenstrom macroglobulinemia (WM) and closely related disorders inc

67 understanding of the biology of Waldenstrom macroglobulinemia (WM) and in therapeutic options for WM

68 e (MGUS), multiple myeloma (MM), Waldenstrom macroglobulinemia (WM) and light chain AL amyloidosis, a

69 omatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight into its biol

70 Familial aggregation of Waldenstrom macroglobulinemia (WM) and related B-cell disorders (BCD

71 mutation is highly prevalent in Waldenstrom macroglobulinemia (WM) and supports malignant growth thr

72 Familial aggregation of Waldenstrom macroglobulinemia (WM) cases, and the clustering of B-ce

73 Waldenstrom macroglobulinemia (WM) cells present with increased expr

74 d to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a

75 on of investigational agents for Waldenstrom macroglobulinemia (WM) has been limited by the lack of i

76 ut the molecular pathogenesis of Waldenstrom macroglobulinemia (WM) has significantly advanced, the p

77 s in the blood of a patient with Waldenstrom macroglobulinemia (WM) indicates the functional importan

78 Waldenstrom macroglobulinemia (WM) is a B-cell disorder characterize

79 Waldenstrom macroglobulinemia (WM) is a B-cell malignancy characteri

80 Waldenstrom macroglobulinemia (WM) is a B-cell malignancy characteri

81 Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested b

82 Waldenstrom macroglobulinemia (WM) is a distinct B-cell disorder res

83 Waldenstrom macroglobulinemia (WM) is a distinct B-cell lymphoprolif

84 Waldenstrom macroglobulinemia (WM) is a distinct B-cell lymphoprolif

85 Waldenstrom's macroglobulinemia (WM) is a distinct clinicobiological e

86 Waldenstrom macroglobulinemia (WM) is a lymphoid neoplasm characteri

87 Waldenstrom macroglobulinemia (WM) is a proliferative disorder of Ig

88 Waldenstrom macroglobulinemia (WM) is a rare, lymphoplasmacytic lymp

89 Waldenstrom macroglobulinemia (WM) is an incurable low-grade B-cell

90 Waldenstrom macroglobulinemia (WM) is an incurable low-grade lymphom

91 Waldenstrom macroglobulinemia (WM) is an incurable low-grade lymphop

92 Waldenstrom macroglobulinemia (WM) is an incurable lymphoplasmacytic

93 Current information on Waldenstrom macroglobulinemia (WM) is based on retrospective or sing

94 Waldenstrom's macroglobulinemia (WM) is characterized by an overproduc

95 Waldenstrom macroglobulinemia (WM) is characterized by widespread in

96 evel genetic characterization of Waldenstrom macroglobulinemia (WM) is required to improve our unders

97 ide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent.

98 tivity and is present in >90% of Waldenstrom macroglobulinemia (WM) patients.

99 , the role of these molecules in Waldenstrom macroglobulinemia (WM) remains poorly understood.

100 The genetic basis for Waldenstrom macroglobulinemia (WM) remains to be clarified.

101 (71%) progressed to symptomatic Waldenstrom macroglobulinemia (WM) requiring treatment, one to prima

102 whole exome-sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high frequency of MYD

103 rates and durable remissions in Waldenstrom macroglobulinemia (WM) that are impacted by MYD88 and CX

104 The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously.

105 f IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma characterized

106 For Waldenstrom macroglobulinemia (WM), a distinct subtype of lymphoplas

107 Waldenstrom macroglobulinemia (WM), a distinctive subtype of non-Hod

108 rmation on the cell of origin in Waldenstrom macroglobulinemia (WM), a longstanding puzzle due to con

109 riate agents in the treatment of Waldenstrom macroglobulinemia (WM), a lymphoplasmacytic lymphoma.

110 eptor type 4 (CXCR4) mutation in Waldenstrom macroglobulinemia (WM), a marker of tumor aggression and

111 Waldenstrom macroglobulinemia (WM), an IgM-associated lymphoplasmacy

112 proximately 95% of patients with Waldenstrom macroglobulinemia (WM), as well as other B-cell malignan

113 reated symptomatic patients with Waldenstrom macroglobulinemia (WM), most of which were of advanced a

114 molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based prote

115 nd its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has been succes

116 l B cell malignancies, including Waldenstrom macroglobulinemia (WM), where elevated IgM is associated

117 Waldenstrom macroglobulinemia (WM), which has an immunoglobulin M (I

118 d recurring somatic mutations in Waldenstrom macroglobulinemia (WM).

119 ding MYD88, CXCR4, and ARID1A in Waldenstrom macroglobulinemia (WM).

120 s an important therapeutic for Waldenstrom's macroglobulinemia (WM).

121 lls derived from patients with Waldenstrom's macroglobulinemia (WM).

122 peripheral neuropathy (PN) in Waldenstrom's macroglobulinemia (WM).

123 eport its aberrant activation in Waldenstrom macroglobulinemia (WM).

124 cal presentation and survival in Waldenstrom macroglobulinemia (WM).

125 ns in MYD88 (L265P) and CXCR4 in Waldenstrom macroglobulinemia (WM).

126 reated symptomatic patients with Waldenstrom macroglobulinemia (WM).

127 atients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

128 recurring somatic mutation in Waldenstrom's macroglobulinemia (WM).

129 me is described in patients with Waldenstrom macroglobulinemia (WM).

130 a (LPL), including IgM-secreting Waldenstrom macroglobulinemia (WM).

131 atients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

132 atients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

133 in (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM).

134 ents with symptomatic, untreated Waldenstrom macroglobulinemia (WM).

135 ing fludarabine and rituximab in Waldenstrom macroglobulinemia (WM).

136 ), multiple myelomas (MM), and Waldenstrom's macroglobulinemias (WM) using protein macroarrays that w

137 mphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma.

138 with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia [WM]), being either absent or present